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Abstract Article Info 
Introduction: Recurrent nasopharyngeal carcinoma is a tumor that relapse after remission is completed whose 
treatment is still a challenge in the medical field because it has a set of medical properties a truly unique pathway. 
It is very important to understand the recurrence of nasopharyngeal carcinoma including the importance of 
improving individual management guidelines as well as a complete evaluation of the quality of life of patients. 
Objective: Statements of purpose of the study. 
Methods: The method carried out in this study is  retrospective descriptive research retrieval from patient’s 
medical record with recurrent nasopharyngeal carcinoma at Oncology Head Neck Surgery of ORL-HNS 
outpatient clinic, Hasan Sadikin General Hospital Bandung from 2017 to 2019. 
Results: Between 2017-2019 period, there were 1.727 outpatient NPC with recurrent NPC were 135 patients 
(7.8%). Most of them were treated by chemotherapy (45%) followed by combination therapy (30%), and 
radiotherapy (25%). 
Conclusion: Most recurrent NCP patients in this study were treated by chemotherapy (45%). Treatment 
techniques should be highly individualized and depend on the site and extent of recurrence, previous treatment, 
and the availability of equipment and expertise. 
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1. INTRODUCTION 
Nasopharyngeal carcinoma (NPC) is a malignancy arising from 
the squamous epithelial cells that cover the surface and line the 
nasopharynx with most common preference site is Rosenmuller 
fossa. Epstein Barr virus (EBV) infection, environmental factors 
and genetic predisposition are proposed to be the main contributing 
factors in endemic regions [1, 2, 3]. Nasopharyngeal carcinoma has 
a place with the main four malignancies after breast, cervical, and 
lung cancer [1]. 
NPC has poor diagnosis and become endemic in specific 
districts of the world, particularly in Southeast Asia. In Indonesia, 
the recorded mean commonness is 6.2/100,000, with 13,000 yearly 
new NPC cases. Between 2010 and 2014 there were 692 patients 
with NPC in Hasan Sadikin Hospital, Bandung with more frequent 
occurrences in male (65.7%) and at the age of 46-55 (29.6%) [1, 3].  
Recurrent nasopharyngeal carcinoma which is a small part of 
head and neck cancers has a distinctive pathomedical pathway so 
that in its management is still remain a challenge [4, 9]. 
Conventional treatments offer limited local control and frequently 
induce severe late complications and most of treatment will fail in 
locoregional or distant sites or both in over 50% of patients at 10 
years [3, 4, 5]. Recent treatment strategies and techniques-
consisting of precision radiotherapy, surgery, third generation 
chemotherapy regimen, and targeted therapies may provide new 
hope for patients with recurrent NPCs [4, 7].  
However, due to lack of existing evidence makes it difficult for 
doctors to apply such techniques and strategies. So it is very 
important to improve individual management guidelines, a complete 
evaluation of the quality of life of patients as well as a further 
understanding of the causes of relapse [4, 8]. 
2. MATERIALS AND METHODS 
The method carried out in this study is retrospective descriptive 
research retrieval from patient’s medical record with recurrent 
nasopharyngeal carcinoma based on inclusion and exclusion criteria. 
Inclusion criteria were all patients diagnosed with recurrent NPC at 
Oncology Head Neck Surgery of ORL-HNS outpatient clinic, Hasan 
Sadikin General Hospital Bandung from 2017 to 2019.  
3. RESULTS 
Between 2017-2019 period, there were 1727 outpatient NPC in 
clinic ORL-HNS oncology division at Hasan Sadikin Hospital 
Bandung and patients who diagnosed with recurrent NPC were 135 
patients (7.8%). Patients consisted of 71% men and 29% women. 
Most patients were found at the age of more than 40 years by 79% 
while those under the age of 40 were 21%. (Table 1) 




Sex   
   Male 96 71 
   Female 39 29 
Age   
   ≤40 28 21 
   ≥40 107 79 
 Table 2 shows that patients generally come in stages III-IV (75%). 
Amount of patient who come with T3-T4 tumors were 76 (56%) and 
T1-T2 were 59 (44%). Based on lymph node metastasis were 69 
patients (51%) at N2-N3 and the remaining were 66 patients (49%) at 
N0-N1. Most of the patients who come have M0 or no metastasis 
(91%) and the rest are M1 (9%). Patients who experienced recurrence 
for less than 24 months were 70 patients (52%) and the rest occurred 
recurrence for more than 24 months were 65 patients (48%). Most 
reccurent NCP patients were treated by chemotherapy (45%) followed 




















T    
  T1-T2 59 44 
  T3-T4 76 56 
N    
  N0-N1 66 49 
  N2-N3 69 51 
M    
  M0 123 91 
  M1 12 9 
Stage   
  I-II 34 25 
  III-IV 101 75 
Interval to recurrence   
  ≤ 24 70 52 
  ≥ 24 65 48 
Therapy   
  Chemotherapy 61 45 
  Radiotherapy 34 25 
  Combination 40 30 
4. DISCUSSION 
In this study showed that more incidence in men compared to women 
with a ratio of 2.3 : 1. These differences may be caused by different lifestyles 
between men and women e.g tobacco intake or biological variations [1]. In 
general, NPCs are more common in older adults than children and young 
adults, with peak incidences over 50 to 60 years of age [3, 9]. 
This study found that 56% of recurrence cases were found in T3-T4. 
This is suitable with study by Xin Jia et.al that showed more than 50% of 
recurrence cases were found in the T3-T4 classification and patient with 
recurrent NPC cases have an 82% risk type of tumor (T) according to the T 
type when first identified. Most of Patients with the recurrence NPC (73.5%) 
found localized in the nasopharyngeal region and followed by lymph node 
metastases in the neck (21.7%), while this study found that recurrence NPC 
patients with N2-N3 lymph node metastases about 51% [11].  
Metastasis develops within 3 years after the initiation therapy and 
following conventional definitive radiotherapy (RT), local recurrence or 
distant metastasis develops in about 20-30 % of patients [16]. The data of 
this study showed most of recurrence NPC patients has no distant metastases 
(M0) while study conducted by Xin Jia.et.al showed that only 6.5% out of 
351 patients who experienced a recurrence of NPC occurred distant 
metastasis and 43.5% experienced bone metastasis. Recurrence patients has 
more serious TNM classification compared to  primary NPC [11, 12]. So, 
Early diagnosis of the recurrent NPC is critical because the result of therapy 
is very dependent on the tumor extension. However, early detection of local 
recurrence of NPC may be clinically challenging because of post irradiated 
local mucosal fibrosis and chronic inflammation [12, 14]. 
Most recurrent NCP patients in this study were treated by chemotherapy 
(45%) followed by combination therapy (30%) and radiotherapy (25%) with 
the regiment used for systemic therapy/chemotherapy are 
ifosfamide+carboplatin/cisplatin+paclitaxel+mesna. The first line therapy 
with a chemotherapeutic drug is especially given to patients with rT3-4 
diseases because this can reduce the mass size of recurrent tumors that 
facilitate sparing adjacent OARs and eradicate micro metastases [9, 13, 14]. 
Extensive research has been done on various chemotherapy agents and 
their combinations in locally recurring settings and varies substantially 
which remains the gold standard is a combination of cisplatin and 
gemcitabine. Systematic review from A Prawira et all. patient undergoing 
systemic therapy has statistically significant improvement with use of 
combination therapy and first-line platinum-containing chemotherapy 
combined with non-platinum regimens. In study conducted by Viktor et al., 
showed first-line treatment of recurrent or metastasis NPC consisted of 
platinum-based chemotherapy (cisplatin or carboplatin) in combination with 
5-fluorouracil (5-FU) or a taxane (docetaxel or paclitaxel)  [7, 10]. 
In the research that has been done mostly shows that to control the 
tumor locally is not enough just given chemotherapy alone, as contained in 
the primary settings. In such conditions it may given adjuvant, but there 
must still be a local therapeutic component for any benefit or possibility of 
rescue [14]. Intensity-modulated radiotherapy (IMRT) technology has 
served as a major breakthrough in the treatment and control local recurrent 
of NPC. [13, 14, 15]. 
Perri et al, in the extensive meta-analysis research conducted by Leong 
et al, in 12 studies, showed results on 1.768 patients with recurrent NPCs 
treated with re-radiation therapy, using IMRT, either with or without 
chemotherapy simultaneously. And the results showed that the 5-year OS 
rate was 41%, suggesting that most patients with local recurrence can 
achieve long-term survival by re-irradiation [17]. 
Re-irradiation therapy (rRT) techniques  consists of 4 techniques, 
namely three-dimensional conformal radiotherapy (3D crt), intensity-
modulated radiation therapy (imrt), stereotactic radiosurgery (srs), and 
fractionated stereotactic radiotherapy (fsrt) that useful for improving local 
control and recurring survival in NPCs. Re-irradiation therapy (rRT) is 
similar to surgery only for small T-stage (T1 and T2) because it is enough to 
protect the organs around the tumor and its utilization is usually limited by 
the degree of disease due to re-irradiation in T3 and T4 recurrent NPCs 
accompanied by high toxicity and low likelihood of response [13, 17]. 
The challenge is considerations related to rRT which are catastrophic 
complications of risk including mucosal necrosis, aspiration pneumonia, 
carotid explosion and temporal lobe necrosis. Given the narrow therapeutic 
margins, it is important to remember that higher doses of radiation may not 
cause the chances of survival to be greater because fatal complications that 
occur can eliminate the benefits of higher levels of tumor control [9, 12, 14]. 
The total dose given has also been shown to be one of the significant factors, 
and based on the calculation shows that the cumulative doses of >100 Gy 
were associated with higher level of severe toxicities [17]. 
Surgery will be difficult in cases of recurrent nasopharyngeal carcinoma. Based 
on previous research, laterocervical metastasis, if alone and isolated, it would be 
better to perform surgery. The surgical strategy relies heavily on the type of 
recurrence and metastasis of the laterocervical lymph nodes that occur where it can 
be treated with optionally available neck dissection [10, 16, 17].   
Currently in some recent studies, one of them is the case reported by You et 
al that endoscopic nasopharyngectomy shows better results compared to salvage 
IMRT i.e. more optimal treatment, better quality of life (QOL) and much lower 
rate of treatment-related complications. In contrast, meta-analysis data conducted 
in 2014 involving 779 patients showed that re-irradiated adjuvant achieved 
additional survival benefits when compared to surgery alone [10]. 
Nowadays, immunotherapy becomes one of the therapeutic options in 
cases of recurrent nasopharyngeal carcinoma, having shown its respective 
efficacy in the first line and in following the therapeutic line, and, 
importantly, NPC is a tumor capable of elicit a strong immune response in 
the host. This is due to viral-induced cancer genesis, which allows in the 
expression of many viral antigens of cancer cells on the surface of the cell. 
LMP-1 and 2, as well as EBNA, are diagnosed with the help of immunity as 
non-self, inducing a significant immune response. However, proper 
immunotherapy function in recurrent NPC management is still not optimal 
and should be evaluated, and for that reason those techniques are still not 
included in the standard of therapy. [9, 17].  
Figure 1 shows the management flowchart relating to the current 



















Figure 1 Flowchart shows the management relating to the current condition 
of recurrent NPC patients. Source: Perri et al.2019 [17] 
 








Most recurrent NCP patients in this study were treated by chemotherapy (45%) 
followed by combination therapy (30%) and radiotherapy (25%). Preference of 
therapies for patients with recurrent NPC varies in clinical practice and depends on 
patients clinical conditions. Treatment strategies should be highly individualized, 
and depend on the site and quality of recurrence, previous treatment, and the 
availability of equipment and expertise.  
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